News | March 10, 2026
Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
The first of four planned modules at the new plant is expected to come online by summer 2026
The first of four planned modules at the new plant is expected to come online by summer 2026
The revenues this quarter are in line with the outlook we envisaged for the year
Granules India receives 1 observation from USFDA for Chantilly facility
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The FDA issued Form 483 with one observation related to building and facility management
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
The inspections concluded with no Form 483 observations or significant critical findings
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
Subscribe To Our Newsletter & Stay Updated
